Redx to test antifibrotic in clinic for NASH in 2020

Redx Pharma plc (LSE:REDX) said its lead Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor reduced collagen deposition in animal models of lung, kidney and liver fibrosis. The company also said the compound has a suitable pharmacokinetics profile for an orally bioavailable drug. Redx will present data at the Non-Alcoholic Steatohepatitis (NASH) Summit in Boston in April...